The board of directors of Lijun International Pharmaceutical (Holding) Co Ltd. announced that the group is expected to record a significant increase in the amount of net profit for the six months ended June 30, 2013 as compared to the amount of net profit for the six months ended June 30, 2012. This significant increase in the amount of net profit is primarily attributable to significant growth of the intravenous infusion solution business of the group in the six months ended June 30, 2013.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.7 HKD | -1.05% | -4.47% | -4.86% |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-4.86% | 1.85B | |
+34.35% | 705B | |
+30.68% | 583B | |
-3.49% | 364B | |
+20.15% | 332B | |
+6.19% | 291B | |
+15.70% | 238B | |
-3.44% | 210B | |
+10.49% | 209B | |
+9.21% | 169B |
- Stock Market
- Equities
- 2005 Stock
- News SSY Group Limited
- Lijun International Pharmaceutical Co Ltd. Provides Group Earnings Guidance for the Six Months Ended June 30, 2013